Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03920254 · ClinicalTrials.gov registry record · Phase 2
TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study
A Phase 2 study, sponsored by Theravance Biopharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT03920254: Clinical Trial Phase 2 study, sponsored by Theravance Biopharma.
NCT03920254 is a Phase 2 study that was terminated before completion, run by Theravance Biopharma. The registered enrollment target is 46 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03920254, a Phase 2 study, was terminated before completion, sponsored by Theravance Biopharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
A 3-Year Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis who have participated in the Maintenance Study of Protocol 0157
Primary Outcome
A TEAE was defined as any AE with a recorded start date on or after the date of the first dose of study drug up through 4 weeks after the last dose of study drug. Any clinically significant changes in laboratory safety tests, electrocardiograms (ECGs) and vital signs, were also recorded as TEAEs.
Interventions
- DRUG TD-1473 Dose A
- DRUG TD-1473 Dose B
- DRUG TD-1473 Dose C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2020-07-23 |
| Est. Completion | 2021-10-27 |
| Phase | Phase 2 |
Why NCT03920254 stopped before completion
NCT03920254 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which TD-1473 Dose A is the first listed.
NCT03920254 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03920254 about?
NCT03920254 is a clinical study titled "TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study". A 3-Year Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis who have participated in the Maintenance Study of Protocol 0157
What is the current status of trial NCT03920254?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2020-07-23. Estimated completion is 2021-10-27.
What interventions are being tested in trial NCT03920254?
The interventions under investigation include: TD-1473 Dose A (DRUG), TD-1473 Dose B (DRUG), TD-1473 Dose C (DRUG).
Who is sponsoring clinical trial NCT03920254?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03920254's enrollment target sits among peer trials
46 1286th of 2000 higher than 705 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI